(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 11.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.69%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.74%.
Biomarin Pharmaceutical's revenue in 2024 is $2,471,644,000.On average, 11 Wall Street analysts forecast BMRN's revenue for 2024 to be $515,291,442,146, with the lowest BMRN revenue forecast at $495,776,165,633, and the highest BMRN revenue forecast at $526,726,573,522. On average, 11 Wall Street analysts forecast BMRN's revenue for 2025 to be $577,959,182,448, with the lowest BMRN revenue forecast at $536,277,527,613, and the highest BMRN revenue forecast at $609,417,328,930.
In 2026, BMRN is forecast to generate $644,222,296,820 in revenue, with the lowest revenue forecast at $555,835,147,322 and the highest revenue forecast at $693,078,370,132.